BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.
METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to …

In previous studies, the diarylquinoline R207910 (also known as TMC207) was
demonstrated to have high bactericidal activity when combined with first-or second-line …

Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …

ABSTRACT PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to
improve tuberculosis (TB) therapy. This randomized study evaluated safety, tolerability …

BACKGROUND: Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor
active against Mycobacterium tuberculosis at a low minimum inhibitory concentration …

Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB,
respectively) continue to represent a challenge for clinicians and public health authorities …

The role of pyrazinamide in the current treatment of multidrug-resistant (MDR) tuberculosis
(TB) is uncertain. From a territory-wide registry of MDR-TB cases diagnosed between 1995 …

There are currently renewed efforts to develop drugs that could shorten the duration of
antituberculosis therapy. This is best achieved by optimizing the sterilizing effect. However …

The commonly accepted hypothesis explaining the mechanism of action of pyrazinamide
(PZA) is based on the assumption that PZA-susceptible Mycobacterium tuberculosis strains …

Background Non-tuberculous mycobacteria (NTM) infections are hard to treat. New
antimicrobial drugs and smarter combination regimens are needed. Objectives Our aim was …